Mirikizumab As a Potential New Treatment in Patients with Crohn’s Disease

Mirikizumab is approved for the treatment of ulcerative colitis. The main objective of the VIVID 1 study was to evaluate the efficacy and the safety of mirikizumab in patients with moderate to severe Crohn’s disease. The results show significant efficacy vs placebo and that mirikizumab also will have its place in patients with Crohn’s disease regardless whether it’s a patient who previously failed or did not fail a biological therapy.